Median OS values were similar for bevacizumab and high-dose linifanib ( bevacizumab , @ months -LSB- @ % CI , @-not available -RSB- ; high-dose linifanib , @ months -LSB- @ % CI , @-@ @ -RSB- ; low-dose linifanib , @ months -LSB- @ % CI , @-@ @ -RSB- ) .